Tobey MacDonald MD
- SOM: Peds: Neuro-Oncology
Professor
- (404) 727-1447
- tobey.macdonald@emory.edu
- MacDonald Laboratory
- Children's Healthcare of Atlanta Provider Profile
-
Aflac Cancer and Blood Disorders Center
Pediatrics
1760 Haygood Drive
Academic Appointment
- Professor of Pediatrics, Emory University
- Program Medical Director of Neuro-Oncology, Children's Healthcare of Atlanta
Education
Degrees
- BA from Cornell University
- MD from Cornell University Medical College
Research
Focus
- The primary research focus is on the mechanism and role of platelet-derived growth factor receptor (PDGFR) signaling in medulloblastoma progression, based on our findings that PDGFR is overexpressed by metastatic medulloblastomas (Nat Genet, 2001) and that PDGFR inhibition in blocks medulloblastoma cell migration (Molec Cancer Ther, 2009)
Publications
-
Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.
Commun Mater Volume: 6 Page(s): 5
01/01/2025 Authors: Mokarram N; Case A; Hossainy NN; Lyon JG; MacDonald TJ; Bellamkonda R -
Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk Disease.
06/28/2024 Authors: Chien F; Michaud ME; Bakhtiari M; Schroff C; Snuderl M; Velazquez Vega JE; MacDonald TJ; Bhasin MK -
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Neuro Oncol Volume: 26 Page(s): S155 - S164
05/03/2024 Authors: Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C -
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
J Clin Oncol Volume: 42 Page(s): 1542 - 1552
05/01/2024 Authors: Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A -
DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines.
Children (Basel) Volume: 11
04/20/2024 Authors: Schniederjan MJ; Potnis C; Vasudevaraja V; Moser CD; Watson B; Snuderl M; MacDonald T; Rogers BB -
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial.
Neuro Oncol Volume: 26 Page(s): 348 - 361
02/02/2024 Authors: Johnson TS; MacDonald TJ; Pacholczyk R; Aguilera D; Al-Basheer A; Bajaj M; Bandopadhayay P; Berrong Z; Bouffet E; Castellino RC -
BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center's experience.
Front Oncol Volume: 14 Page(s): 1505951
01/01/2024 Authors: McThenia SS; Reddy KM; Damaraju E; Castellino E; He Z; Beers R; Chien F; Castellino RC; Goldman-Yassen AE; Fangusaro JR -
Visual outcomes after bevacizumab-based therapy for optic pathway glioma.
Pediatr Blood Cancer Volume: 70 Page(s): e30668
12/01/2023 Authors: Siegel BI; Nelson D; Peragallo JH; MacDonald TJ; Wolf DS -
The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma tumor growth and survival.
Mol Oncol Volume: 17 Page(s): 1784 - 1802
09/01/2023 Authors: Shahab SW; Roggeveen CM; Sun J; Kunhiraman H; McSwain LF; Juraschka K; Kumar SA; Saulnier O; Taylor MD; Schniederjan M -
Author Correction: YB1 modulates the DNA damage response in medulloblastoma.
Sci Rep Volume: 13 Page(s): 9717
06/15/2023 Authors: McSwain LF; Pillsbury CE; Haji-Seyed-Javadi R; Rath SK; Chen V; Huang T; Shahab SW; Kunhiraman H; Ross J; Price GA